Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load

•Cobas 6800 results correlated well with those of Cobas TaqMan for HIV, HBV and HCV.•However, Cobas 6800 tended to yield higher viremia for HIV and lower for HBV.•For HCV, Cobas 6800 gave lower or higher values depending on the area of the range.•Discrepancies are observed between Cobas 6800 and Abb...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2017-11, Vol.96, p.49-53
Main Authors: Wirden, Marc, Larrouy, Lucile, Mahjoub, Nadia, Todesco, Eve, Damond, Florence, Delagreverie, Heloise, Akhavan, Sepideh, Charpentier, Charlotte, Chaix, Marie-Laure, Descamps, Diane, Calvez, Vincent, Marcelin, Anne-Genevieve
Format: Article
Language:English
Subjects:
Abbott RealTime assay
Cobas 6800/8800
HBV DNA quantification
HCV RNA quantification
Hepacivirus - isolation & purification
Hepatitis B virus - isolation & purification
HIV - isolation & purification
HIV RNA quantification
Humans
Life Sciences
Molecular Diagnostic Techniques - methods
Roche Cobas Ampliprep/Cobas TaqMan
Viral Load - methods
Viremia - diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Cobas 6800 results correlated well with those of Cobas TaqMan for HIV, HBV and HCV.•However, Cobas 6800 tended to yield higher viremia for HIV and lower for HBV.•For HCV, Cobas 6800 gave lower or higher values depending on the area of the range.•Discrepancies are observed between Cobas 6800 and Abbott Realtime for HCV. The new Roche Cobas 6800 platform (C6800) has been recently introduced for viral load (VL) measurement. Comparing C6800 to Cobas Ampliprep/Cobas TaqMan v2.0 (CAP/CTM) for the quantification of HIV, HBV and HCV viremia, and to the Abbott RealTime assay (ABB) for HCV quantification. We analysed 121 samples for HBV, and 139 for HIV-1 including 2 groupO and 137 group M viruses (36.5% subtype B, 27.0% CRF02_AG, 22.6% from other clades, and 14% subtype not available). For the 100 HCV samples compared with CAP/CTM, 42% were genotype 1 and 17% were genotype 4. For the 68 HCV samples compared with ABB, 52.9% were genotype 1 and 22.1% were genotype 4. C6800 results correlated well with those of CAP/CTM for all three viruses (R2: 0.97–0.99). However, C6800 can yield different viraemia results: higher for HIV (mean difference: +0.11 log10copies/mL, p
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2017.09.007